Shimadzu Corporation

7701.T
Scientific & Technical Instruments
2026/08/06 Updated
Market Cap: $7.5B (¥1.2T)
Stock Price: $26.06 (¥4,111)
Exchange Rate: 1 USD = ¥157.73

Q1 FY2027 Financial Summary (Consolidated) under Japanese GAAP

For the first quarter of the fiscal year ending March 2027, net sales were 130,596 million yen, up 10.3% YoY; operating income was 14,264 million yen, up 17.1% YoY; ordinary income was 18,486 million yen, up 63.3% YoY; net income attributable to owners of the parent was 13,333 million yen, up 68.3% YoY. Full-year earnings guidance was revised; pre-goodwill and other amortization operating income is expected to be 85,000 million yen. The overseas mix increased, and segments including measuring instruments, medical devices, industrial devices, and aircraft equipment remained solid. The impact of business combinations, including the acquisition of Tescan Group, is noted.

Importance:
Page Updated: August 6, 2026
IR Disclosure Date: August 6, 2026

Key Figures

  • Net sales: 130,596 million yen
  • Operating income: 14,264 million yen
  • Net income attributable to owners of the parent: 13,333 million yen

AI要約

Overview of results

Shimadzu Corporation achieved significant top- and bottom-line growth in the first quarter of the fiscal year ending March 2027, with net sales of 130,596 million yen (up 10.3% YoY), operating income of 14,264 million yen (up 17.1% YoY), ordinary income of 18,486 million yen (up 63.3% YoY), and net income attributable to owners of the parent of 13,333 million yen (up 68.3% YoY). Segments, including measuring instruments, medical devices, industrial devices, and aircraft equipment, remained solid. The impact of business combinations including the Tescan Group acquisition is noted.

Outlook and capital plan

Full-year consolidated earnings guidance has been revised upward; pre-goodwill and other amortization operating income is expected to be 85,000 million yen. While affected by exchange rates, the company will benefit from a weaker yen, capturing growth in semiconductor-related demand globally and the pharmaceutical market, while expanding recurring revenue businesses. An upward revision reflecting the Tescan Group acquisition is implemented.

Revenue Trend

Operating Income Trend

Net Income Trend

Pre-Goodwill Amortization Operating Margin

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Shimadzu Corporation

Company overview · Stock price · Financial data · All IR

View company page →